Accessibility Menu
Cypherpunk Technologies logo

Cypherpunk Technologies(NASDAQ) LPTX

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-99%
5 Year-95%
1 Year+85%
1 Month+1%
Cypherpunk Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.662026-07-23
Cypherpunk Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.23%USD 0.712026-07-16
1 month+1.27%USD 0.652026-06-23
3 month-33.9%USD 1.002026-04-24
Year to date-43.02%USD 1.162025-12-31
1 year+85.05%USD 0.362025-07-23
3 year-77.59%USD 2.952023-07-24
5 year-95.21%USD 13.802021-07-23
Since inception-99.16%USD 78.602017-01-25

Cypherpunk Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$209.00K

Net Income (TTM)

-$56.91M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 18, 2026

LPTX News

Foolcom-Featured.png

Leap Therapeutics Slashes R&D Spending

Motley Fool Markets TeamAug 14, 2025
happy-investor-phone-at-home-sofa-getty

Why Leap Therapeutics Stock Is Surging Today

Cory RenauerJan 19, 2022
rich kid

2 Risky Growth Stocks That Could Make You Filthy Rich

George Budwell, PhDJan 16, 2022
scientist-biotech-comparing-test-tubes-getty

3 Biotech Stocks That Surged in September

Cory RenauerOct 5, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cypherpunk Technologies

Leap Therapeutics develops antibody therapies to help treat cancer. Its main product aims to block proteins that help tumors grow. These therapies are designed for patients with hard-to-treat cancers.

What’s in the Leap Toolbox?

  • Sirexatamab (DKN-01): Antibody therapy in clinical trials for several cancers, including stomach, liver, and prostate. 0% of revenue, as no product sales to date.
  • FL-501: Early-stage antibody program, not yet in human trials. 0% of revenue.
  • Legacy Programs: TRX518, FL-301, FL-302; minimal or no current activity or spending.
  • Partnerships: Option and license agreement with BeiGene for DKN-01 in Asia-Pacific (excluding Japan), Australia, and New Zealand.

Leap’s Growth Spurts (and Stumbles)

  • Signed option and license deal with BeiGene in 2020 for DKN-01 in Asia-Pacific.
  • Expanded clinical trials for sirexatamab (DKN-01) across multiple cancer types since 2021.
  • Engaged Raymond James & Associates in 2025 to explore mergers, asset sales, or partnerships.
  • Reduced workforce by approximately 75% in Q2 2025 to cut costs and preserve cash.

What Makes Leap a Bit Different?

Leap focuses on antibody therapies that target specific proteins linked to cancer growth. Its main drug candidate aims to block a pathway found in several hard-to-treat cancers. The company relies on partnerships and government R&D incentives to support its research.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $17 million in Q2 2025, improving 20.6% from Q2 2024.
  • Cash and equivalents were $12 million in Q2 2025, down 83.2% from Q2 2024.

Bottom Line

Leap has focused its resources on a single lead cancer therapy and reduced costs to extend its runway. The company’s future depends on securing new funding or strategic deals.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Doug E. Onsi

Website

www.leaptx.com

Headquarters

Cambridge, MA 02141, US

LPTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-46.86%

Return on Capital

-23.80%

Return on Assets

-65.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$20.13M

Operating Income

-$29.97M

EBITDA

-$29.72M

Operating Cash Flow

-$77.65M

Capital Expenditure

-$1.99M

Free Cash Flow

-$79.65M

Cash & ST Invst.

$6.69M

Total Debt

$38.00K

Cypherpunk Technologies Performance Analysis

Cypherpunk Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cypherpunk Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
Cypherpunk Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.822.0%
20232023-12-31USD -3.98-17.4%
20242024-12-31USD -1.81-54.7%
20252025-12-31USD 0.07N/A
Cypherpunk Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8.1%
Q32025-09-3080.0%
Q42025-12-311250.0%
Q12026-03-31-150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

52

N/A

Net Income

-$77.17M

-399.9%

EBITDA

-$4.82M

+68.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.69M

-79.6%

Total Debt

$38.00K

-75.3%

Accounts Receivable

$74.47M

+10373.3%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$38.00K

-75.3%

Return on Assets

-65.13%

N/A

Return on Invested Capital

-35.52%

N/A

Free Cash Flow

-$3.43M

+76.3%

Operating Cash Flow

-$3.43M

+76.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTXRCitius Pharmaceuticals, Inc.
$0.52-2.07%
ATHAAthira Pharma, Inc.
$6.75-6.12%
CRISCuris, Inc.
$4.89+4.71%
PCSAProcessa Pharmaceuticals, Inc.
$2.60-9.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%
CLFCleveland-Cliffs
$11.93+0.09%

Questions About LPTX

What is the current price of Cypherpunk Technologies?

Cypherpunk Technologies is trading at N/A per share.

What is the 52-week range for Cypherpunk Technologies?

Over the past 52 weeks, Cypherpunk Technologies has traded between N/A and N/A.

How much debt does Cypherpunk Technologies have?

As of the most recent reporting period, Cypherpunk Technologies reported total debt of $38.00K.

How much cash does Cypherpunk Technologies have on hand?

Cypherpunk Technologies reported $6.69M in cash and cash equivalents in its most recent financial results.

What is Cypherpunk Technologies’s dividend yield?

Cypherpunk Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services